Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Dose-Dense Gemcitabine and Cisplatin in MIBC
NCT07184021Phase 2Not yet recruiting
- Sponsor
- Assiut University
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in muscle-invasive bladder cancer (MIBC), sponsored by Assiut University. Primary endpoint: Pathologic Complete Response Rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07184021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184021.